^Gagnon C, Gomez-Mancilla B, Markstein R, Bédard PJ, Di Paolo T (1995). „Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors”. Progress in Neuro-psychopharmacology & Biological Psychiatry. 19 (4): 667—76. PMID8588064.
^Beninger RJ, Rolfe NG (1995). „Dopamine D1-like receptor agonists impair responding for conditioned reward in rats”. Behavioural Pharmacology. 6 (8): 785—793. PMID11224381.
^Luquin MR, Guillén J, Legarda I, Cruz Rodriguez M, Del Rio L, Dominguez J, Martínez-Lage JM (1996). „Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys”. Advances in Neurology. 69: 239—44. PMID8615134.
^D'Aquila PS, Panin F, Cossu M, Peana AT, Serra G (2003). „Dopamine D1 receptor agonists induce penile erections in rats”. European Journal of Pharmacology. 460 (1): 71—4. PMID12535862. doi:10.1016/S0014-2999(02)02881-9.
^Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A, Betz A (2005). „Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243”. Behavioural Brain Research. 156 (2): 173—9. PMID15582103. doi:10.1016/j.bbr.2004.05.019.
